The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial
Open accessAbstract
OBJECTIVE: To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women. DESIGN: Open label, randomised controlled trial. SETTING: Denmark, 1990-93. PARTICIPANTS: 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with recorded postmenopausal serum follicle stimulating hormone values. 502 women were randomly allocated to receive hormone replacement therapy and 504 to receive no treatment (control). Women who had undergone hysterectomy were included if they were aged 45-52 and had recorded values for postmenopausal serum follicle stimulating hormone. INTERVENTIONS: In the treatment group, women with an intact uterus were treated with triphasic estradiol and norethisterone acetate and women who had undergone hysterectomy received 2 mg estradiol a day. Intervention was stopped after about 11 years owing to adverse reports from other trials, but participants were followed for death, cardiovascular disease, and cancer for up to 16 years. Sensitivity analyses were carried out on women who took more than 80% of the prescribed treatment for five years. MAIN OUTCOME MEASURE: The primary endpoint was a composite of death, admission to hospital for heart failure, and myocardial infarction. RESULTS: At inclusion the women on average were aged 50 and had been postmenopausal for seven months. After 10 years of intervention, 16 women in the treatment group experienced the primary composite endpoint compared with 33 in the control group (hazard ratio 0.48, 95% confidence interval 0.26 to 0.87; P=0.015) and 15 died compared with 26 (0.57, 0.30 to 1.08; P=0.084). The reduction in cardiovascular events was not associated with an increase in any cancer (36 in treated group v 39 in control group, 0.92, 0.58 to 1.45; P=0.71) or in breast cancer (10 in treated group v 17 in control group, 0.58, 0.27 to 1.27; P=0.17). The hazard ratio for deep vein thrombosis (2 in treated group v 1 in control group) was 2.01 (0.18 to 22.16) and for stroke (11 in treated group v 14 in control group) was 0.77 (0.35 to 1.70). After 16 years the reduction in the primary composite outcome was still present and not associated with an increase in any cancer. CONCLUSIONS: After 10 years of randomised treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke. TRIAL REGISTRATION: ClinicalTrials.gov NCT00252408.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Pharmacology of estrogens and progestogens: influence of different routes of administration
Kuhl, H. (2005) · Climacteric · doi:10.1080/13697130500148875 · Cited by 835
Estrogen in the Prevention of Atherosclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Hodis, H. N., Mack, W. J., Lobo, R. A., Shoupe, D., Sevanian, A., Mahrer, P. R., Selzer, R. H., Liu, C.-R., Liu, C.-H., Azen, S. P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00005 · Cited by 687
Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative
Hsia, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 610
Miller, V. T., LaRosa, J. C., Barnabei, V. M., Kessler, C. M., Levin, G., Smith-Roth, A., Griffin, M. E., Stoy, D. B., Bush, T. L., Zacur, H. A., et al. (1995) · JAMA · doi:10.1001/jama.273.3.199 · Cited by 601
LaCroix, A. Z. (2011) · JAMA · doi:10.1001/jama.2011.382 · Cited by 538
The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
GRODSTEIN, F., & STAMPFER, M. (1995) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(95)80012-3 · Cited by 417
KEEPS: The Kronos Early Estrogen Prevention Study
Harman, S., Brinton, E., Cedars, M., Lobo, R., Manson, J., Merriam, G., Miller, V., Naftolin, F., & Santoro, N. (2005) · Climacteric · doi:10.1080/13697130500042417 · Cited by 397
Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women
Hodis, H. N., Mack, W. J., Azen, S. P., Lobo, R. A., Shoupe, D., Mahrer, P. R., Faxon, D. P., Cashin-Hemphill, L., Sanmarco, M. E., French, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030830 · Cited by 386
Salpeter, S. R., Walsh, J. M. E., Greyber, E., & Salpeter, E. E. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00389.x · Cited by 364
Mortality associated with hormone replacement therapy in younger and older women: A meta-analysis
Salpeter, S. R., Walsh, J. M. E., Greyber, E., Ormiston, T. M., & Salpeter, E. E. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30281.x · Cited by 292
DUBEY, R., IMTHURN, B., BARTON, M., & JACKSON, E. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.012 · Cited by 240
Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause
Prentice, R. L., Manson, J. E., Langer, R. D., Anderson, G. L., Pettinger, M., Jackson, R. D., Johnson, K. C., Kuller, L. H., Lane, D. S., Wactawski-Wende, J., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp115 · Cited by 234
Bayesian Meta-analysis of Hormone Therapy and Mortality in Younger Postmenopausal Women
Salpeter, S. R., Cheng, J., Thabane, L., Buckley, N. S., & Salpeter, E. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.021 · Cited by 201
Sare, G. M., Gray, L. J., & Bath, P. M. W. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn299 · Cited by 188
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000275404.76075.72 · Cited by 160
Mosekilde, L., Beck-Nielsen, H., Sørensen, O. H., Nielsen, S. P., Charles, P., Vestergaard, P., Hermann, A. P., Gram, J., Hansen, T. B., Abrahamsen, B., et al. (2000) · Maturitas · doi:10.1016/s0378-5122(00)00158-4 · Cited by 160
Self-citationFournier, A., Mesrine, S., Boutron‐Ruault, M., & Clavel‐Chapelon, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6432 · Cited by 142
Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women
Prentice, R. L., Chlebowski, R. T., Stefanick, M. L., Manson, J. E., Pettinger, M. B., Hendrix, S. L., Hubbell, F. A., Kooperberg, C. L., Kuller, L. H., Lane, D. S., et al. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn044 · Cited by 140
Rosano, G. M. C., Webb, C. M., Chierchia, S. L., Morgani, G. L., Gabraele, M., Sarrel, P. M., de Ziegler, D., & Collins, P. D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01007-x · Cited by 124
Jensen, L., Vestergaard, P., Hermann, A., Gram, J., Eiken, P., Abrahamsen, B., Brot, C., Kolthoff, N., Sørensen, O., Beck-Nielsen, H., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.333 · Cited by 119
Self-citationHormone replacement therapy for preventing cardiovascular disease in post-menopausal women
Sánchez, R. G., Sánchez-Gómez, L. M., Carmona, L., Figuls, M. R. I., & Bonfill, X. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub2 · Cited by 89
Avenell, A., GRANT, A. M., McGee, M., McPherson, G. C., Campbell, M., McGee, M. A., & RECORD Trial Management Group (2004) · Clinical Trials · doi:10.1191/1740774504cn053oa · Cited by 87
Kristensen, K., Pedersen, S. B., Vestergaard, P., Mosekilde, L., & Richelsen, B. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1630055 · Cited by 84
Self-citationHodis, H. N., & Mack, W. J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.076 · Cited by 83
Mosekilde, L., Hermann, A., Beck‐Nielsen, H., Charles, P., Nielsen, S. P., & Sørensen, O. H. (1999) · Maturitas · doi:10.1016/s0378-5122(99)00006-7 · Cited by 77
Self-citationEstrogen for women at varying risk of coronary disease
Grodstein, F., & Stampfer, M. J. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00055-3 · Cited by 69
Improving compliance with hormonal replacement therapy in primary osteoporosis prevention
Vestergaard, P., Hermann, A. P., Gram, J., Jensen, L. B., Kolthoff, N., Abrahamsen, B., Brot, C., & Eiken, P. (1997) · Maturitas · doi:10.1016/s0378-5122(97)00076-5 · Cited by 58
Self-citationNovensà, L., Selent, J., Pastor, M., Sandberg, K. L., Heras, M., & Dantas, A. P. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.151969 · Cited by 53
Jayachandran, M., Mukherjee, R., Steinkamp, T., LaBreche, P. T., Bracamonte, M. P., Okano, H., Owen, W. G., & Miller, V. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01108.2004 · Cited by 48
Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women
Gužič‐Salobir, B., Keber, I., Seljeflot, I., Arnesen, H., & Dežman, L. V. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00910.x · Cited by 44
In vitro effects of progesterone and progestins on vascular cells
Simoncini, T., Mannella, P., Fornari, L., Caruso, A., Varone, G. L., & Genazzani, A. R. (2003) · Steroids · doi:10.1016/j.steroids.2003.08.006 · Cited by 43
Alexandersen, P., Haarbo, J., Sandholdt, I., Shalmi, M., Lawaetz, H., & Christiansen, C. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.6.902 · Cited by 41
Conjugated Equine Estrogens and Coronary Heart Disease: The Women???s Health Initiative
Hsia, J. A., Langer, R. D., Manson, J. E., Kuller, L. H., Johnson, K., Hendrix, S. L., Pettinger, M. B., Heckbert, S. R., Greep, N. C., Crawford, S. L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000219472.72978.7a · Cited by 31
Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy
Norris, L., Joyce, M., O'Keeffe, N., SHEPPARD, B. L., & Bonnar, J. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00202-5 · Cited by 29
Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women
Hodis, H. N., Mack, W. J., & Azen, S. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.09.014 · Cited by 13
Taner, M. Z., Özpolat, E., Taşkıran, Ç., Onan, M. A., Gursel, T., Karabulut, E., Gursoy, R., & Himmetoğlu, Ö. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.05.010 · Cited by 10
Cited by
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Cardiovascular Risks Associated with Gender and Aging
Rodgers, J. L., Jones, J., Bolleddu, S. I., Vanthenapalli, S., Rodgers, L. E., Shah, K., Karia, K., & Panguluri, S. K. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6020019 · Cited by 1,024
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Metadata
- Authors
- Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Kober, L., & Jensen, J.-E. B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2012-10-09
- Volume
- 345
- Issue
- oct09 2
- Pages
- e6409-e6409
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2089358310
- Cited by
- 747
- References
- 43
- FWCI
- 55.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.